Save time and jump to the most important pieces.
4 - LIPELLA PHARMACEUTICALS INC. (0001347242) (Issuer)
4 - LIPELLA PHARMACEUTICALS INC. (0001347242) (Issuer)
4 - LIPELLA PHARMACEUTICALS INC. (0001347242) (Issuer)
4 - LIPELLA PHARMACEUTICALS INC. (0001347242) (Issuer)
4 - LIPELLA PHARMACEUTICALS INC. (0001347242) (Issuer)
10-Q - LIPELLA PHARMACEUTICALS INC. (0001347242) (Filer)
8-K - LIPELLA PHARMACEUTICALS INC. (0001347242) (Filer)
PRE 14A - LIPELLA PHARMACEUTICALS INC. (0001347242) (Filer)
SC 13G/A - LIPELLA PHARMACEUTICALS INC. (0001347242) (Subject)
SC 13G/A - LIPELLA PHARMACEUTICALS INC. (0001347242) (Subject)
SC 13D/A - LIPELLA PHARMACEUTICALS INC. (0001347242) (Subject)
Shares of ASP Isotopes Inc. (NASDAQ:ASPI) fell during Friday's session after the company announced pricing of a $30 million public offering of 12 million shares at $2.50 per share. ASP Isotopes shares fell 9.2% to $3.2308 on Friday. Here are some other stocks moving in today’s mid-day session. Gainers Vicinity Motor Corp. (NASDAQ:VEV) shares jumped 133.2% to $0.7910 after the company announced CARB certification for the VMC 1200 class 3 electric truck. Qualigen Therapeutics, Inc. (NASDAQ:QLGN) shares rose 110% to $0.4335. TOYO Co., Ltd (NASDAQ:TOYO) climbed 63.4% to $2.5322. Nisun International Enterprise Development Group Co., Ltd (NASDAQ:NISN) jumped 58% to $9.52 foll
Shares of Telefonaktiebolaget LM Ericsson (NASDAQ:ERIC) rose sharply in today's pre-market trading after the company reported better-than-expected second-quarter sales and issued guidance. Ericsson reported a second-quarter loss of 31 cents per share, compared to year-ago earnings of 7 cents per share. The company reported quarterly sales of $5.59 billion which beat the analyst consensus estimate of $5.36 billion, according to data from Benzinga Pro. Ericsson shares jumped 4.3% to $6.66 in pre-market trading. Here are some other stocks moving in pre-market trading. Gainers Sentage Holdings Inc. (NASDAQ:SNTG) rose 85.6% to $4.27 in pre-market trading after gaining around 5% on
PITTSBURGH, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) ("Lipella" or the "Company"), a clinical-stage biotechnology company focused on innovative therapies for serious diseases with significant unmet needs, today announced the completion of dosing for the first cohort in its multi-center Phase 2a clinical trial of LP-310, a liposomal-tacrolimus oral rinse being developed for the treatment of Oral Lichen Planus (OLP). In this first cohort, eight participants received a dose of 0.25 mg LP-310, with promising initial results. No product-related serious adverse events were reported. Pharmacokinetic data demonstrated that whole blood tacrolimus levels in all p
PITTSBURGH, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (NASDAQ:LIPO), a clinical-stage biotechnology company focused on developing innovative therapies for serious diseases with unmet medical needs, today announced that U.S. Patent No. 12,138,345 for its proprietary liposomal drug delivery platform will be officially issued by the U.S. Patent and Trademark Office (USPTO) on November 12, 2024. This patent, titled "Delivery of Agents Using Metastable Liposomes," covers key technological innovations that enable the targeted delivery of therapeutic agents using liposome-based vehicles. The patent's claims cover Lipella's method of using metastable liposomes to deliver th
PITTSBURGH, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) (the "Company," "our" or "us"), a clinical-stage biotechnology company focused on developing innovative therapies for serious diseases with unmet medical needs, today announced that it intends to effect a 1-for-8 reverse stock split of its common stock effective as of 5:00 p.m. Eastern Time on November 7, 2024 upon the filing of a certificate of amendment to the Company's certificate of incorporation with the Secretary of State of the State of Delaware. The Company expects that its common stock will begin trading on a split-adjusted basis when the market opens on November 8, 2024, under its current tra